Arcutis Biotherapeutics (ARQT) Change in Accured Expenses (2019 - 2026)

Arcutis Biotherapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $20.8 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 9804.67% year-over-year to $20.8 million; the TTM figure through Mar 2026 stood at $71.0 million (up 120.91% YoY), while the FY2025 annual figure was $50.0 million, up 56.23% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $20.8 million, down from $23.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $23.5 million in Q4 2025, with the low at -$5.5 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $5.9 million (2023), against an average of $6.4 million.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses sank 234.77% in 2023, then surged 9804.67% in 2026.
• Arcutis Biotherapeutics' Change in Accured Expenses stood at $616000.0 in 2022, then soared by 860.55% to $5.9 million in 2023, then jumped by 122.8% to $13.2 million in 2024, then surged by 77.9% to $23.5 million in 2025, then dropped by 11.44% to $20.8 million in 2026.
• Business Quant data shows ARQT's Change in Accured Expenses at $20.8 million in Q1 2026, $23.5 million in Q4 2025, and $5.6 million in Q3 2025.